Free Trial

Entera Bio (ENTX) Competitors

Entera Bio logo
$2.22 +0.08 (+3.74%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$2.16 -0.06 (-2.48%)
As of 10/24/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENTX vs. NGNE, EOLS, BNTC, AMRN, RCKT, KRRO, KMDA, IVVD, AURA, and REPL

Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Neurogene (NGNE), Evolus (EOLS), Benitec Biopharma (BNTC), Amarin (AMRN), Rocket Pharmaceuticals (RCKT), Korro Bio (KRRO), Kamada (KMDA), Invivyd (IVVD), Aura Biosciences (AURA), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

Entera Bio vs. Its Competitors

Entera Bio (NASDAQ:ENTX) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by insiders. Comparatively, 11.6% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neurogene has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Neurogene's return on equity of -33.33% beat Entera Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Entera Bio-4,525.11% -77.75% -68.13%
Neurogene N/A -33.33%-30.34%

Entera Bio presently has a consensus target price of $10.00, indicating a potential upside of 350.45%. Neurogene has a consensus target price of $46.17, indicating a potential upside of 54.46%. Given Entera Bio's higher possible upside, equities analysts clearly believe Entera Bio is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Neurogene
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Entera Bio has higher earnings, but lower revenue than Neurogene. Entera Bio is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entera Bio$180K563.14-$9.54M-$0.26-8.54
Neurogene$930K458.63-$75.14M-$4.31-6.94

In the previous week, Entera Bio had 5 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.91 beat Entera Bio's score of 1.00 indicating that Neurogene is being referred to more favorably in the news media.

Company Overall Sentiment
Entera Bio Positive
Neurogene Very Positive

Entera Bio has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Summary

Neurogene beats Entera Bio on 10 of the 17 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTX vs. The Competition

MetricEntera BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$101.37M$3.46B$6.22B$10.81B
Dividend YieldN/A2.28%5.72%4.81%
P/E Ratio-8.5428.2931.5030.91
Price / Sales563.14497.18594.92133.93
Price / CashN/A46.9537.2561.86
Price / Book9.6510.4012.056.61
Net Income-$9.54M-$52.83M$3.34B$277.10M
7 Day Performance-5.53%2.10%1.93%2.57%
1 Month Performance24.02%12.33%7.77%3.79%
1 Year Performance18.09%14.14%56.40%33.01%

Entera Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTX
Entera Bio
2.1033 of 5 stars
$2.22
+3.7%
$10.00
+350.5%
+22.0%$101.37M$180K-8.5420News Coverage
Positive News
Analyst Forecast
NGNE
Neurogene
1.8612 of 5 stars
$32.16
+10.8%
$46.17
+43.6%
-38.0%$414.32MN/A-7.4690Analyst Forecast
EOLS
Evolus
4.1196 of 5 stars
$6.69
+4.5%
$21.25
+217.6%
-57.0%$413.99M$266.27M-6.83170
BNTC
Benitec Biopharma
1.6657 of 5 stars
$16.23
+3.7%
$24.80
+52.8%
+51.1%$410.82M$80K-11.0420News Coverage
Analyst Forecast
AMRN
Amarin
0.9759 of 5 stars
$20.25
+3.1%
$12.00
-40.7%
+71.5%$406.21M$228.61M-5.52360News Coverage
Upcoming Earnings
Analyst Forecast
RCKT
Rocket Pharmaceuticals
4.9001 of 5 stars
$4.00
+7.8%
$16.67
+316.7%
-77.6%$400.32MN/A-1.59240Analyst Forecast
Gap Up
KRRO
Korro Bio
2.5571 of 5 stars
$46.35
+10.0%
$86.83
+87.3%
-44.1%$395.83M$2.27M-4.7570Gap Up
KMDA
Kamada
4.6789 of 5 stars
$7.08
+4.9%
$13.00
+83.6%
+29.3%$388.16M$160.95M20.82360News Coverage
Positive News
Analyst Forecast
IVVD
Invivyd
4.1748 of 5 stars
$1.97
+13.2%
$5.14
+160.8%
+125.5%$373.07M$46.21M-2.14100Positive News
AURA
Aura Biosciences
1.9486 of 5 stars
$6.06
+6.9%
$20.50
+238.3%
-47.9%$352.22MN/A-3.0950
REPL
Replimune Group
4.3729 of 5 stars
$8.94
+98.7%
$11.00
+23.0%
-26.4%$351.25MN/A-2.76210Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ENTX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners